Piramal Pharma gains after receiving EIR for Turbhe facility from USFDA

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

30 May 2025 00:00:00

Adani Ports

1432.35

(-0.39%)

Asian Paints

2260.05

(-1.62%)

Axis Bank

1192.05

(-0.82%)

Bajaj Finance

9174.75

(-0.32%)

Bajaj Finserv

2015.80

(0.25%)

Bharti Airtel

1856.80

(-0.38%)

Eternal Ltd

238.75

(4.58%)

HCL Technologi..

1637.55

(-1.64%)

HDFC Bank

1944.60

(0.81%)

Hind. Unilever

2349.35

(-0.78%)

ICICI Bank

1445.95

(-0.73%)

IndusInd Bank

817.10

(-0.86%)

Infosys

1562.80

(-1.43%)

ITC

417.90

(-0.20%)

Kotak Mah. Ban..

2075.70

(-0.41%)

Larsen & Toubr..

3675.75

(0.56%)

M & M

2978.45

(-0.90%)

Maruti Suzuki

12317.55

(-0.55%)

Nestle India

2396.75

(-1.52%)

NTPC

334.25

(-1.49%)

Power Grid Cor..

289.90

(-1.13%)

Reliance Indus..

1420.80

(0.24%)

St Bk of India

812.40

(1.89%)

Sun Pharma.Ind..

1678.30

(-1.27%)

Tata Motors

719.45

(-0.69%)

Tata Steel

161.00

(-1.29%)

TCS

3464.50

(-0.94%)

Tech Mahindra

1574.00

(-1.62%)

Titan Company

3554.20

(-0.96%)

UltraTech Cem.

11197.25

(-0.61%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Piramal Pharma gains after receiving EIR for Turbhe facility from USFDA	Share Back
(12 May 2025)
According to the company’s exchange filing, the US FDA conducted a general Good Manufacturing Practices (GMP) inspection at the Turbhe facility from 11 February to 17 February 2025. Following the inspection, the US FDA has issued an EIR with a classification of voluntary action indicated (VAI). The receipt of the EIR signifies the successful closure of the inspection. Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The pharmaceutical company’s consolidated net profit tumbled 63.6% to Rs 3.68 crore despite a 12.54% increase in revenue from operations to Rs 2,204.22 crore in Q3 FY25 over Q3 FY24.
Top